ARTICLE | Clinical News
Exocell, Genentech regulatory update
January 3, 1995 8:00 AM UTC
GNE was granted a right of first negotiation for a worldwide exclusive license to Exocell’s A717 compound to treat diabetic nephropathy. GNE (South San Francisco) will assess the efficacy of A717 in a...